Advancing RRMM Care With T-cell Redirecting Therapies: Current Landscape and Future Directions
Saturday, May 16th, 14:50-16:05
The objectives of this session are to:
- Understand optimal treatment approaches between CAR-T cell therapies and bispecific antibodies for managing relapsed/refractory multiple myeloma (RRMM), including their effectiveness, safety, and real-world utilization and outcomes
- Examine what unmet needs remain in the RRMM treatment landscape in the post-B-cell maturation antigen setting with regard to efficacy and safety considerations, non-BCMA targeting therapies, and sequencing strategies
- Review new and investigational treatments, along with associated clinical data, to assess their potential clinical utility in the 2L+ RRMM setting
| AGENDA | |
|---|---|
| 14:50-14:55 | Welcome and introductionWelcome and Overview of Key Issues for Debate in the RRMM Space Alexis Talbot, MD; France |
| 14:55-15:25 |
Debating the Optimal T-Cell Redirecting Approach: CAR T-Cell Therapies vs BsAbs
Faculty Roundtable Discussion Salomon Manier, MD, PhD; France
|
| 15:25-15:50 |
Addressing Unmet Needs After BCMA-Directed Therapy
Faculty Roundtable Discussion
Krina Patel, MD, MS; United States
|
| 15:50-16:00 | Potential New Treatments on the Horizon Alexis Talbot, MD; France |
| 16:00-16:05 |
Q&A
All faculty
|
HE-FR-2600013
